SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR

Alice C. Eastman, Rhonda G. Pace, Hong Dang, Melis Atalar Aksit, Briana Vecchio-Pagán, Anh Thu N. Lam, Wanda K. O'Neal, Scott M. Blackman, Michael R. Knowles, Garry R. Cutting

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The CFTR modulator ivacaftor has been variably effective in treating individuals with cystic fibrosis (CF) who harbor CFTR gating variants such as G551D, as well as other classes of CFTR variants when used with other modulators. Because CFTR genotype does not fully explain this variability, defining genetic modifiers of response to modulator therapy is of particular interest to the field of individualized CF drug therapy. Previous studies have proposed that a variant in SLC26A9 (rs7512462) is associated with lung disease severity and with response to treatment with ivacaftor in individuals with CF who carry G551D or gating variants. Methods: Given the implications for CF treatment, we re-examined the reported associations in three cohorts; patients enrolled in the Twin and Siblings study at Johns Hopkins University, the CF modifier study at the University of North Carolina at Chapel Hill, and the prospective G551D Observational (GOAL) study. The GOAL study was specifically designed to measure lung function response to ivacaftor. Results: We find no association between SLC26A9 (rs7512462) genotype and lung disease severity (n = 272) or change in lung function at one-, three-, and six-month intervals following ivacaftor treatment(n = 141) in individuals with CF who carry at least one G551D variant. Conclusions: Our inability to replicate this association indicates that rs7512462 genotype should not be used in treatment decisions.

Original languageEnglish (US)
Pages (from-to)851-856
Number of pages6
JournalJournal of Cystic Fibrosis
Volume20
Issue number5
DOIs
StatePublished - Sep 2021

Keywords

  • G551D
  • Ivacaftor efficacy
  • Modifier genes
  • SLC26A9 rs7512462

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR'. Together they form a unique fingerprint.

Cite this